Research progress of proteasome inhibitors in treatment of multiple myeloma

Abstract

Multiple myeloma(MM) cases constitute a relatively high proportion of patients suffering from hematological malignant diseases, with its prevalence rate mounting every year. Substantial breakthrough of MM treatment has been achieved due to the development of proteasome inhibitors(PI), which facilitates cellular apoptosis induced by the accumulation of intracellular ubiquitinated and/or misfolded proteins, via the inhibition of the degradation of the apoptosis-associated proteins. The exact pharmaceutical mechanisms of different PI vary, leading to different therapeutic effects and drug adverse reactions. Further understanding of the pharmaceutical mechanisms, therapeutic effects and safety of various PI lays the theoretical foundation for their clinical use. This article focuses the research progress and the clinical application of PIs in terms of MM treatment. Key words: Multiple myeloma; Proteasome inhibitors; Bortezomib; Carfilzomib; Ixazomib